Global Vesicoureteral Reflux Treatment Market
Global Vesicoureteral Reflux Treatment Market

Vesicoureteral Reflux Treatment Comprehensive Study by Type (Primary VUR, Secondary VUR), Treatment (Medicinal Treatment (Antibiotics and Anticholinergics), Minimally Invasive Surgical Treatment), End User (Hospitals, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2026

Vesicoureteral Reflux Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 208 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Vesicoureteral Reflux Treatment Market Overview:
The global vesicoureteral reflux treatment market is expected to grow due to the increasing prevalence and incidence of urinary tract infections, nephrolithiasis, and abdominal sepsis. The rising number of births combined with hospital-acquired infections of the urinary tract would help the industry generate revenue. The growth of the industry would be supported by increased awareness and access to surgical procedures and medications.

Growth Drivers
  • High Prevalence and Increasing Incidence Rates of Urinary Tract Infections
  • Increasing Birth Rates with Hospital-acquired Infections related to Urinary Tracts


Roadblocks
  • Side Effects of long term use of antibiotics and fewer diagnosis rates of VUR

Opportunities
  • Rising Number of Patients Relying on Post-surgical Drugs
  • Increase in the Diagnostic Sector through Radiological Equipment, Serological Screening and Birth Monitoring Techniques

Challenges
  • Lack of Awareness among People


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Cook Group Incorporated (United States), Q-MED AB (Sweden), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Inc. (India), Allegis Holdings, LLC (United States), Alvogen, Inc. (United States), Vernalis Therapeutics, Inc. (United States) and Janssen Pharmaceuticals, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Vesicoureteral Reflux Treatment market by 2026. Considering Market by Treatment, the sub-segment i.e. Medicinal Treatment (Antibiotics and Anticholinergics) will boost the Vesicoureteral Reflux Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Vesicoureteral Reflux Treatment market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Vesicoureteral Reflux Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Vesicoureteral Reflux Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Vesicoureteral reflux treatment Service Providers, Vesicoureteral reflux treatment Drug Providers, Pharmaceutical Industry, Academic Institutions, Consulting Firms and Regulatory Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Primary VUR
  • Secondary VUR
By Treatment
  • Medicinal Treatment (Antibiotics and Anticholinergics)
  • Minimally Invasive Surgical Treatment

By End User
  • Hospitals
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence and Increasing Incidence Rates of Urinary Tract Infections
      • 3.2.2. Increasing Birth Rates with Hospital-acquired Infections related to Urinary Tracts
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among People
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Vesicoureteral Reflux Treatment, by Type, Treatment, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Vesicoureteral Reflux Treatment (Value)
      • 5.2.1. Global Vesicoureteral Reflux Treatment by: Type (Value)
        • 5.2.1.1. Primary VUR
        • 5.2.1.2. Secondary VUR
      • 5.2.2. Global Vesicoureteral Reflux Treatment by: Treatment (Value)
        • 5.2.2.1. Medicinal Treatment (Antibiotics and Anticholinergics)
        • 5.2.2.2. Minimally Invasive Surgical Treatment
      • 5.2.3. Global Vesicoureteral Reflux Treatment by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Vesicoureteral Reflux Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Vesicoureteral Reflux Treatment (Price)
      • 5.3.1. Global Vesicoureteral Reflux Treatment by: Type (Price)
  • 6. Vesicoureteral Reflux Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Cook Group Incorporated (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Q-MED AB (Sweden)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sun Pharmaceutical Industries Inc. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allegis Holdings, LLC (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Alvogen, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Vernalis Therapeutics, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Janssen Pharmaceuticals, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Vesicoureteral Reflux Treatment Sale, by Type, Treatment, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Vesicoureteral Reflux Treatment (Value)
      • 7.2.1. Global Vesicoureteral Reflux Treatment by: Type (Value)
        • 7.2.1.1. Primary VUR
        • 7.2.1.2. Secondary VUR
      • 7.2.2. Global Vesicoureteral Reflux Treatment by: Treatment (Value)
        • 7.2.2.1. Medicinal Treatment (Antibiotics and Anticholinergics)
        • 7.2.2.2. Minimally Invasive Surgical Treatment
      • 7.2.3. Global Vesicoureteral Reflux Treatment by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Vesicoureteral Reflux Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Vesicoureteral Reflux Treatment (Price)
      • 7.3.1. Global Vesicoureteral Reflux Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Vesicoureteral Reflux Treatment: by Type(USD Million)
  • Table 2. Vesicoureteral Reflux Treatment Primary VUR , by Region USD Million (2015-2020)
  • Table 3. Vesicoureteral Reflux Treatment Secondary VUR , by Region USD Million (2015-2020)
  • Table 4. Vesicoureteral Reflux Treatment: by Treatment(USD Million)
  • Table 5. Vesicoureteral Reflux Treatment Medicinal Treatment (Antibiotics and Anticholinergics) , by Region USD Million (2015-2020)
  • Table 6. Vesicoureteral Reflux Treatment Minimally Invasive Surgical Treatment , by Region USD Million (2015-2020)
  • Table 7. Vesicoureteral Reflux Treatment: by End User(USD Million)
  • Table 8. Vesicoureteral Reflux Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 9. Vesicoureteral Reflux Treatment Specialty Clinics , by Region USD Million (2015-2020)
  • Table 10. Vesicoureteral Reflux Treatment Others , by Region USD Million (2015-2020)
  • Table 11. South America Vesicoureteral Reflux Treatment, by Country USD Million (2015-2020)
  • Table 12. South America Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 13. South America Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 14. South America Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 15. Brazil Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 16. Brazil Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 17. Brazil Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 18. Argentina Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 19. Argentina Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 20. Argentina Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 21. Rest of South America Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 23. Rest of South America Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 24. Asia Pacific Vesicoureteral Reflux Treatment, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 27. Asia Pacific Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 28. China Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 29. China Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 30. China Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 31. Japan Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 32. Japan Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 33. Japan Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 34. India Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 35. India Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 36. India Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 37. South Korea Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 38. South Korea Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 39. South Korea Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 40. Taiwan Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 41. Taiwan Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 42. Taiwan Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 43. Australia Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 44. Australia Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 45. Australia Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 49. Europe Vesicoureteral Reflux Treatment, by Country USD Million (2015-2020)
  • Table 50. Europe Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 51. Europe Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 52. Europe Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 53. Germany Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 54. Germany Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 55. Germany Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 56. France Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 57. France Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 58. France Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 59. Italy Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 60. Italy Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 61. Italy Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 62. United Kingdom Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 64. United Kingdom Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 65. Netherlands Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 66. Netherlands Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 67. Netherlands Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 68. Rest of Europe Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 70. Rest of Europe Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 71. MEA Vesicoureteral Reflux Treatment, by Country USD Million (2015-2020)
  • Table 72. MEA Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 73. MEA Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 74. MEA Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 75. Middle East Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 76. Middle East Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 77. Middle East Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 78. Africa Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 79. Africa Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 80. Africa Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 81. North America Vesicoureteral Reflux Treatment, by Country USD Million (2015-2020)
  • Table 82. North America Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 83. North America Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 84. North America Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 85. United States Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 86. United States Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 87. United States Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 88. Canada Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 89. Canada Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 90. Canada Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 91. Mexico Vesicoureteral Reflux Treatment, by Type USD Million (2015-2020)
  • Table 92. Mexico Vesicoureteral Reflux Treatment, by Treatment USD Million (2015-2020)
  • Table 93. Mexico Vesicoureteral Reflux Treatment, by End User USD Million (2015-2020)
  • Table 94. Vesicoureteral Reflux Treatment: by Type(USD/Units)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Vesicoureteral Reflux Treatment: by Type(USD Million)
  • Table 104. Vesicoureteral Reflux Treatment Primary VUR , by Region USD Million (2021-2026)
  • Table 105. Vesicoureteral Reflux Treatment Secondary VUR , by Region USD Million (2021-2026)
  • Table 106. Vesicoureteral Reflux Treatment: by Treatment(USD Million)
  • Table 107. Vesicoureteral Reflux Treatment Medicinal Treatment (Antibiotics and Anticholinergics) , by Region USD Million (2021-2026)
  • Table 108. Vesicoureteral Reflux Treatment Minimally Invasive Surgical Treatment , by Region USD Million (2021-2026)
  • Table 109. Vesicoureteral Reflux Treatment: by End User(USD Million)
  • Table 110. Vesicoureteral Reflux Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 111. Vesicoureteral Reflux Treatment Specialty Clinics , by Region USD Million (2021-2026)
  • Table 112. Vesicoureteral Reflux Treatment Others , by Region USD Million (2021-2026)
  • Table 113. South America Vesicoureteral Reflux Treatment, by Country USD Million (2021-2026)
  • Table 114. South America Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 115. South America Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 116. South America Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 117. Brazil Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 118. Brazil Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 119. Brazil Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 120. Argentina Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 121. Argentina Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 122. Argentina Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 123. Rest of South America Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 124. Rest of South America Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 125. Rest of South America Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 126. Asia Pacific Vesicoureteral Reflux Treatment, by Country USD Million (2021-2026)
  • Table 127. Asia Pacific Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 128. Asia Pacific Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 129. Asia Pacific Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 130. China Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 131. China Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 132. China Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 133. Japan Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 134. Japan Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 135. Japan Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 136. India Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 137. India Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 138. India Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 139. South Korea Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 140. South Korea Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 141. South Korea Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 142. Taiwan Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 143. Taiwan Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 144. Taiwan Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 145. Australia Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 146. Australia Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 147. Australia Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 148. Rest of Asia-Pacific Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 151. Europe Vesicoureteral Reflux Treatment, by Country USD Million (2021-2026)
  • Table 152. Europe Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 153. Europe Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 154. Europe Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 155. Germany Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 156. Germany Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 157. Germany Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 158. France Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 159. France Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 160. France Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 161. Italy Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 162. Italy Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 163. Italy Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 164. United Kingdom Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 165. United Kingdom Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 166. United Kingdom Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 167. Netherlands Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 168. Netherlands Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 169. Netherlands Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 170. Rest of Europe Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 171. Rest of Europe Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 172. Rest of Europe Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 173. MEA Vesicoureteral Reflux Treatment, by Country USD Million (2021-2026)
  • Table 174. MEA Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 175. MEA Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 176. MEA Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 177. Middle East Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 178. Middle East Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 179. Middle East Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 180. Africa Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 181. Africa Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 182. Africa Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 183. North America Vesicoureteral Reflux Treatment, by Country USD Million (2021-2026)
  • Table 184. North America Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 185. North America Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 186. North America Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 187. United States Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 188. United States Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 189. United States Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 190. Canada Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 191. Canada Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 192. Canada Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 193. Mexico Vesicoureteral Reflux Treatment, by Type USD Million (2021-2026)
  • Table 194. Mexico Vesicoureteral Reflux Treatment, by Treatment USD Million (2021-2026)
  • Table 195. Mexico Vesicoureteral Reflux Treatment, by End User USD Million (2021-2026)
  • Table 196. Vesicoureteral Reflux Treatment: by Type(USD/Units)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Vesicoureteral Reflux Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Vesicoureteral Reflux Treatment: by Treatment USD Million (2015-2020)
  • Figure 6. Global Vesicoureteral Reflux Treatment: by End User USD Million (2015-2020)
  • Figure 7. South America Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 8. Asia Pacific Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 9. Europe Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 10. MEA Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 11. North America Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 12. Global Vesicoureteral Reflux Treatment: by Type USD/Units (2015-2020)
  • Figure 13. Global Vesicoureteral Reflux Treatment share by Players 2020 (%)
  • Figure 14. Global Vesicoureteral Reflux Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Vesicoureteral Reflux Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Cook Group Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 18. Cook Group Incorporated (United States) Revenue: by Geography 2020
  • Figure 19. Q-MED AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 20. Q-MED AB (Sweden) Revenue: by Geography 2020
  • Figure 21. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2020
  • Figure 23. Sun Pharmaceutical Industries Inc. (India) Revenue, Net Income and Gross profit
  • Figure 24. Sun Pharmaceutical Industries Inc. (India) Revenue: by Geography 2020
  • Figure 25. Allegis Holdings, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 26. Allegis Holdings, LLC (United States) Revenue: by Geography 2020
  • Figure 27. Alvogen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Alvogen, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Vernalis Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Vernalis Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Janssen Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Janssen Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Global Vesicoureteral Reflux Treatment: by Type USD Million (2021-2026)
  • Figure 34. Global Vesicoureteral Reflux Treatment: by Treatment USD Million (2021-2026)
  • Figure 35. Global Vesicoureteral Reflux Treatment: by End User USD Million (2021-2026)
  • Figure 36. South America Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 37. Asia Pacific Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 38. Europe Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 39. MEA Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 40. North America Vesicoureteral Reflux Treatment Share (%), by Country
  • Figure 41. Global Vesicoureteral Reflux Treatment: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Cook Group Incorporated (United States)
  • Q-MED AB (Sweden)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Sun Pharmaceutical Industries Inc. (India)
  • Allegis Holdings, LLC (United States)
  • Alvogen, Inc. (United States)
  • Vernalis Therapeutics, Inc. (United States)
  • Janssen Pharmaceuticals, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation